BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 35400527)

  • 21. Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis.
    Yarza R; Bover M; Herrera-Juarez M; Rey-Cardenas M; Paz-Ares L; Lopez-Martin JA; Haanen J
    Oncologist; 2023 Jun; 28(6):e406-e415. PubMed ID: 37036865
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
    Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
    Hwu P; Yang JC; Cowherd R; Treisman J; Shafer GE; Eshhar Z; Rosenberg SA
    Cancer Res; 1995 Aug; 55(15):3369-73. PubMed ID: 7614473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adoptive tumor infiltrating lymphocytes cell therapy for cervical cancer.
    Zhu Y; Zhou J; Zhu L; Hu W; Liu B; Xie L
    Hum Vaccin Immunother; 2022 Nov; 18(5):2060019. PubMed ID: 35468048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
    Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
    J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficiency and safety of autologous chimeric antigen receptor T-cells therapy used for patients with lymphoma: A systematic review and meta-analysis.
    Cao G; Lei L; Zhu X
    Medicine (Baltimore); 2019 Oct; 98(42):e17506. PubMed ID: 31626107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor infiltrating lymphocyte therapy for ovarian cancer and renal cell carcinoma.
    Andersen R; Donia M; Westergaard MC; Pedersen M; Hansen M; Svane IM
    Hum Vaccin Immunother; 2015; 11(12):2790-5. PubMed ID: 26308285
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Generation of neoantigen-specific T cells for adoptive cell transfer for treating head and neck squamous cell carcinoma.
    Wei T; Leisegang M; Xia M; Kiyotani K; Li N; Zeng C; Deng C; Jiang J; Harada M; Agrawal N; Li L; Qi H; Nakamura Y; Ren L
    Oncoimmunology; 2021 May; 10(1):1929726. PubMed ID: 34104546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell-based immunotherapy in gynecologic malignancies.
    Schaar B; Krishnan V; Tallapragada S; Dorigo O
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):23-30. PubMed ID: 29227304
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
    Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
    Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adoptive Cellular Therapy with Autologous Tumor-Infiltrating Lymphocytes and T-cell Receptor-Engineered T Cells Targeting Common p53 Neoantigens in Human Solid Tumors.
    Kim SP; Vale NR; Zacharakis N; Krishna S; Yu Z; Gasmi B; Gartner JJ; Sindiri S; Malekzadeh P; Deniger DC; Lowery FJ; Parkhurst MR; Ngo LT; Ray S; Li YF; Hill V; Florentin M; Masi RV; Paria BC; Levin N; Bera A; Hedges EA; Choi A; Chatani PD; Parikh AY; Levi S; Seitter S; Lu YC; Zheng Z; Prickett TD; Jia L; Hernandez JM; Hoang CD; Robbins PF; Goff SL; Sherry RM; Yang JC; Rosenberg SA
    Cancer Immunol Res; 2022 Aug; 10(8):932-946. PubMed ID: 35749374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.
    Ramachandran I; Lowther DE; Dryer-Minnerly R; Wang R; Fayngerts S; Nunez D; Betts G; Bath N; Tipping AJ; Melchiori L; Navenot JM; Glod J; Mackall CL; D'Angelo SP; Araujo DM; Chow WA; Demetri GD; Druta M; Van Tine BA; Grupp SA; Abdul Razak AR; Wilky B; Iyengar M; Trivedi T; Winkle EV; Chagin K; Amado R; Binder GK; Basu S
    J Immunother Cancer; 2019 Oct; 7(1):276. PubMed ID: 31651363
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical feasibility and treatment outcomes with nonselected autologous tumor-infiltrating lymphocyte therapy in patients with advanced cutaneous melanoma.
    Pillai M; Jiang Y; Lorigan PC; Thistlethwaite FC; Thomas M; Kirillova N; Bridgeman JS; Kueberuwa G; Biswas S; Velazquez P; Chonzi D; Guest RD; Roberts ZJ; Hawkins RE
    Am J Cancer Res; 2022; 12(8):3967-3984. PubMed ID: 36119832
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunotherapy in Gynecologic Cancers: Are We There Yet?
    Pakish JB; Jazaeri AA
    Curr Treat Options Oncol; 2017 Aug; 18(10):59. PubMed ID: 28840453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer immunotherapy using tumor antigen-reactive T cells.
    Choi BK; Kim SH; Kim YH; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):235-245. PubMed ID: 29370726
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Enrichment of CD8+ cells from melanoma tumor-infiltrating lymphocyte cultures reveals tumor reactivity for use in adoptive cell therapy.
    Prieto PA; Durflinger KH; Wunderlich JR; Rosenberg SA; Dudley ME
    J Immunother; 2010 Jun; 33(5):547-56. PubMed ID: 20463593
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
    Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA
    Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adherent cell depletion promotes the expansion of renal cell carcinoma infiltrating T cells with optimal characteristics for adoptive transfer.
    Braun MW; Abdelhakim H; Li M; Hyter S; Pessetto Z; Koestler DC; Pathak HB; Dunavin N; Godwin AK
    J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33037114
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.